辉瑞(PFE.US)股价涨超2% 与特朗普达成药品定价协议

Core Viewpoint - Pfizer's stock price has increased by over 2.3%, reaching $24.4, following the announcement of a drug pricing agreement with President Trump, which allows the company to sell its medications at lower prices through the Medicaid program [1] Group 1 - Pfizer's stock performance shows a positive market reaction, indicating investor confidence in the company's pricing strategy [1] - The agreement with the U.S. government may enhance Pfizer's market position by making its drugs more accessible to a broader patient population [1] - The announcement reflects ongoing discussions around drug pricing reform in the U.S. healthcare system, which could impact the pharmaceutical industry as a whole [1]